Clinical trial · Interventional
Impact of Virtual Reality on the Quality of Life of Oncology Patients
NCT06485869CI-TRIAL-00078510VIRONSCAREunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anxiety, nausea and vomiting are common side effects in paediatric patients receiving chemotherapy. chemotherapy. New evidence supports the efficacy of immersive virtual reality in improving symptoms of anxiety and distress, including nausea and vomiting, in this vulnerable group. This research will evaluate the efficacy of virtual reality in managing anxiety, nausea and vomiting in cancer patients receiving their first line of chemotherapy and will also measure the quality of life of these patients and evaluate patient and nursing staff satisfaction
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| measurement of acute nausea and vomiting | Other | — | UNRESOLVED |
| Measurement of anxiety and pain | Other | — | UNRESOLVED |
| Measurement of depressive state | Other | — | UNRESOLVED |
| Measure the improvement in quality of life | Other | — | UNRESOLVED |
| Measure the level of satisfaction of patients and nursing staff | Other | — | UNRESOLVED |
| measuring fatigue levels | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- With virtual reality session
- description
- Arm A patients will benefit from a 20-minute virtual reality session per chemotherapy session, for the first 3 cycles, with each session lasting more than 30 minutes.
- interventionNames
- Other: Measure the improvement in quality of life
- Other: Measure the level of satisfaction of patients and nursing staff
- Other: Measurement of anxiety and pain
- Other: Measurement of depressive state
- Other: measuring fatigue levels
- Other: measurement of acute nausea and vomiting
- type
- OTHER
- label
- Without virtual reality session
- description
- Patients in arm B will receive conventional care without hypnotic support.
- interventionNames
- Other: Measure the improvement in quality of life
- Other: Measure the level of satisfaction of patients and nursing staff
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Chemotherapy-naive patient * Patient with first-line indication for intravenous cyclic chemotherapy * Affiliated to a social security system * Having received full information on the organization of the research and having given free, informed and written consent signed by the participant and the investigator * Patient understands French or English * Expected duration of chemotherapy session for the first 3 cycles greater than 30 minutes exclusion criteria : * Patient with communication disorders preventing informed consent * Patient under legal protection (guardianship, curatorship, safeguard of justice) * Patients suffering from epilepsy * Severe visual or hearing impairment preventing use of headphones * Psychiatric pathologies such as delusional disorders, hallucinations or schizophrenia. * Patients with infections or facial wounds * Patients with severe claustrophobia * Patients with pacemakers * Patients with known cognitive or learning problems, * Patients with brain tumors or metastases, * Patients suffering from motion sickness * Expected duration of chemotherapy session for the first 3 cycles of 30 minutes or less.
References
Publications (26)
- BACKGROUNDSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- BACKGROUNDColonna M, Boussari O, Cowppli-Bony A, Delafosse P, Romain G, Grosclaude P, Jooste V; French Network of Cancer Registries (FRANCIM). Time trends and short term projections of cancer prevalence in France. Cancer Epidemiol. 2018 Oct;56:97-105. doi: 10.1016/j.canep.2018.08.001. Epub 2018 Aug 17. PMID 30125884
- BACKGROUNDCarnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S. Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21. PMID 29270827
- BACKGROUNDSchneider SM, Workman ML. Effects of virtual reality on symptom distress in children receiving chemotherapy. Cyberpsychol Behav. 1999;2(2):125-34. doi: 10.1089/cpb.1999.2.125. PMID 19178248
- BACKGROUNDChan A, Kim HK, Hsieh RK, Yu S, de Lima Lopes G Jr, Su WC, Banos A, Bhatia S, Burke TA, Keefe DM. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer. 2015 Jan;23(1):283-91. doi: 10.1007/s00520-014-2375-0. Epub 2014 Aug 13. PMID 25112561
- BACKGROUNDMolassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, Aapro M. Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study. J Pain Symptom Manage. 2016 Jun;51(6):987-93. doi: 10.1016/j.jpainsymman.2015.12.317. Epub 2016 Feb 16.